title: Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?
authors.forename: Jesper Grau
authors.initials: JG
authors.lastname: Eriksen
authors.forename: Pernille
authors.initials: P
authors.lastname: Lassen
authors.forename: Jens
authors.initials: J
authors.lastname: Overgaard
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D015415:Biomarkers; D000068818:Cetuximab; D003131:Combined Modality Therapy; D019941:Cyclin-Dependent Kinase Inhibitor p16; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy* / Q000821:virology*; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins; D030361:Papillomavirus Infections / Q000150:complications*; D018579:Patient Selection
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015415:Biomarkers; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins; D000068818:Cetuximab